← Back to headlines
Neurocrine to Acquire Soleno for Drug Targeting Relentless Hunger Disorder
Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, expanding Neurocrine's therapeutic portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Manila Water prepares for summer heat and high demand
just now
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now